JAK2抑制剂：虽非下一个伊马替尼，但研究人员看到了其他可能性。 - Suppr

JAK2 inhibitors: not the next imatinib but researchers see other possibilities.

作者信息

Garber Ken

出版信息

J Natl Cancer Inst. 2009 Jul 15;101(14):980-2. doi: 10.1093/jnci/djp216. Epub 2009 Jul 7.

DOI:10.1093/jnci/djp216

PMID:19584324

Abstract

摘要

相似文献

JAK2 inhibitors: not the next imatinib but researchers see other possibilities.

J Natl Cancer Inst. 2009 Jul 15;101(14):980-2. doi: 10.1093/jnci/djp216. Epub 2009 Jul 7.

[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].

Ugeskr Laeger. 2006 Sep 25;168(39):3299-303.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Orv Hetil. 2006 Nov 12;147(45):2175-9.

A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.

Leuk Res. 2010 Apr;34(4):e94-6. doi: 10.1016/j.leukres.2009.09.025. Epub 2009 Oct 14.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Cancer. 2003 Jun 1;97(11):2760-6. doi: 10.1002/cncr.11416.

The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.

Hematol Oncol Clin North Am. 2017 Aug;31(4):613-626. doi: 10.1016/j.hoc.2017.04.002. Epub 2017 May 17.

[Tyrosine kinase inhibitors in the treatment of polycythemia vera and related conditions. Danish Society of Hematology].

Ugeskr Laeger. 2008 Mar 17;170(12):1031.

Imatinib effect on growth and signal transduction in polycythemia vera.

Exp Hematol. 2007 Jun;35(6):931-8. doi: 10.1016/j.exphem.2007.03.012.

An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.

Chin Med J (Engl). 2008 Sep 20;121(18):1838-42.

JAK2 kinase inhibitors and myeloproliferative disorders.

Curr Opin Hematol. 2010 Mar;17(2):110-6. doi: 10.1097/MOH.0b013e3283366b91.

引用本文的文献

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

Blood. 2020 Jan 16;135(3):191-207. doi: 10.1182/blood.2019895326.

Novel therapies for myelofibrosis.

Leuk Lymphoma. 2015;56(10):2768-78. doi: 10.3109/10428194.2015.1037762. Epub 2015 May 18.

Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Leukemia. 2014 Nov;28(11):2139-47. doi: 10.1038/leu.2014.176. Epub 2014 Jun 3.

Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Leuk Res. 2011 May;35(5):608-13. doi: 10.1016/j.leukres.2010.07.031. Epub 2010 Aug 19.

Mast cell homeostasis and the JAK-STAT pathway.

Genes Immun. 2010 Dec;11(8):599-608. doi: 10.1038/gene.2010.35. Epub 2010 Jun 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

JAK2 inhibitors: not the next imatinib but researchers see other possibilities.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献